Abstract:Vitiligo is an acquired chronic depigmenting disorder of the skin, with an estimated prevalence of 0.5% of the general population, characterized by the development of white macules resulting from a loss of epidermal melanocytes. The nomenclature has been revised after an extensive international work within the vitiligo global issues consensus conference, and vitiligo (formerly non-segmental vitiligo) is now a consensus umbrella term for all forms of generalized vitiligo. Two other subsets of vitiligo are segmental vitiligo and unclassified/undetermined vitiligo, which corresponds to focal disease and rare variants. A series of hypopigmented disorders may masquerade as vitiligo, and some of them need to be ruled out by specific procedures including a skin biopsy. Multiple mechanisms are involved in melanocyte disappearance, namely genetic predisposition, environmental triggers, metabolic abnormalities, impaired renewal, and altered inflammatory and immune responses. The auto-immune/inflammatory theory is the leading hypothesis because (1) vitiligo is often associated with autoimmune diseases; (2) most vitiligo susceptibility loci identified through genome-wide association studies encode immunomodulatory proteins; and (3) prominent immune cell infiltrates are found in the perilesional margin of actively depigmenting skin. However, other studies support melanocyte intrinsic abnormalities with poor adaptation of melanocytes to stressors leading to melanocyte instability in the basal layer, and release of danger signals important for the activation of the immune system. Recent progress in the understanding of immune pathomechanisms opens interesting perspectives for innovative treatment strategies. The proof of concept in humans of targeting of the IFNγ /Th1 pathway is much awaited. The interplay between oxidative stress and altered immune responses suggests that additional strategies aiming at limiting type I interferon activation pathway as background stabilizing therapies could be an interesting approach in vitiligo. This review covers classification and clinical aspects, pathophysiology with emphasis on immunopathogenesis, and promising therapeutic approaches.

Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer

Vitiligo: A focus on pathogenesis and its therapeutic implications

An update on Vitiligo pathogenesis

A view of dataflow*

Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy

Current Concepts of Vitiligo Immunopathogenesis

[Therapy of patients of cerebral motor disorders].

Vitiligo: Mechanisms of Pathogenesis and Treatment

The enigma and challenges of vitiligo pathophysiology and treatment

The Role of Oxidative Stress in Vitiligo: An Update on Its Pathogenesis and Therapeutic Implications

Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo

Vitiligo, reactive oxygen species and T-cells

Physiopathology and genetics of vitiligo

Future needs--diagnostic services.

Melanocyte-keratinocyte cross-talk in vitiligo

Oxidative Stress-Induced HMGB1 Release from Melanocytes: A Paracrine Mechanism Underlying the Cutaneous Inflammation in Vitiligo

Role of Cytokines and Chemokines in Vitiligo and Their Therapeutic Implications

Mitochondrial Impairment in Peripheral Blood Mononuclear Cells During the Active Phase of Vitiligo

Role of Cytokines in Vitiligo: Pathogenesis and Possible Targets for Old and New Treatments

Post-translational modification in the pathogenesis of vitiligo

Fluctuations in FSH and LH content of the anterior pituitary of the castrated adult female and puerperal rat.